AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advan...

ανά Papadimitrakopoulou, Vassiliki A
Τόπος έκδοσης Lung Cancer Manag (2016)

Optimizing Biomarkers and Endpoints in Oral Cancer Chemoprevention Trials

ανά William, William N., Papadimitrakopoulou, Vassiliki A.
Έκδοση 2013

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

ανά Shien, Kazuhiko, Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio I.
Τόπος έκδοσης Lung Cancer (2016)

Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development

ανά Gu, Xuemin, Chen, Nan, Wei, Caimiao, Liu, Suyu, Papadimitrakopoulou, Vassiliki A., Herbst, Roy S., Lee, J. Jack
Τόπος έκδοσης Stat Biosci (2014)

Phase II Chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions

ανά William, William N., Lee, J. Jack, Lippman, Scott M., Martin, Jack W., Tran, Hai T., Sabichi, Anita L., Kim, Edward S., Feng, Lei, Papadimitrakopoulou, Vassiliki A.
Έκδοση 2009

Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC)

ανά Brooks, Heather D., Glisson, Bonnie S., Bekele, B. Nebiyou, Ginsberg, Lawrence E., El-Naggar, Adel, Culotta, Kirk S., Takebe, Naoko, Wright, John, Tran, Hai T., Papadimitrakopoulou, Vassiliki A.
Έκδοση 2010

Challenges and approaches to implementing master/basket trials in oncology

ανά Burd, Amy, Schilsky, Richard L., Byrd, John C., Levine, Ross L., Papadimitrakopoulou, Vassiliki A., Herbst, Roy S., Redman, Mary W., Druker, Brian J., Gandara, David R.
Τόπος έκδοσης Blood Adv (2019)

Role of COX-2 in tumor progression and survival of head and neck squamous cell carcinoma

ανά Saba, Nabil F., Choi, Misun, Muller, Susan, Shin, Hyung Ju C., Tighiouart, Mourad, Papadimitrakopoulou, Vassiliki A, El-Naggar, Adel K, Khuri, Fadlo R., Chen, Zhuo (Georgia), Shin, Dong M.
Έκδοση 2009

An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia

ανά Rudin, Charles M., Cohen, Ezra E.W., Papadimitrakopoulou, Vassiliki A., Silverman, Sol, Recant, Wendy, El-Naggar, Adel K., Stenson, Kirsten, Lippman, Scott M., Hong, Waun Ki, Vokes, Everett E.
Τόπος έκδοσης J Clin Oncol (2003)

An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer()

ανά Haynes, Brian C., Blidner, Richard A., Cardwell, Robyn D., Zeigler, Robert, Gokul, Shobha, Thibert, Julie R., Chen, Liangjing, Fujimoto, Junya, Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio I., Latham, Gary J.
Τόπος έκδοσης Transl Oncol (2019)

Randomized Trial of 13-cis Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral Premalignancy

ανά Papadimitrakopoulou, Vassiliki A., Lee, J. Jack, William, William N., Martin, Jack W., Thomas, Margaret, Kim, Edward S., Khuri, Fadlo R., Shin, Dong M., Feng, Lei, Hong, Waun Ki, Lippman, Scott M.
Έκδοση 2009

SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-...

ανά Edelman, Martin J., Redman, Mary W., Albain, Kathy S., McGary, Eric C., Rafique, Noman M., Petro, Daniel, Waqar, Saiama N., Minichiello, Katherine, Miao, Jieling, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Τόπος έκδοσης J Thorac Oncol (2019)

Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

ανά Langer, Corey J., Redman, Mary W., Wade, James L., Aggarwal, Charu, Bradley, Jeffrey D., Crawford, Jeffrey, Stella, Philip J., Knapp, Mark H., Miao, Jieling, Minichiello, Katherine, Herbst, Roy S., Kelly, Karen, Gandara, David R., Papadimitrakopoulou, Vassiliki A.
Τόπος έκδοσης J Thorac Oncol (2019)

Brief Report: SWOG S1400D (), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activ...

ανά Aggarwal, Charu, Redman, Mary W., Lara, Primo N., Borghaei, Hossein, Hoffman, Philip, Bradley, Jeffrey D., Newman, Alfred J., Feldman, Marvin J., Minichiello, Katherine, Miao, Jieling, Mack, Philip C., Papadimitrakopoulou, Vassiliki A., Herbst, Roy S., Kelly, Karen, Gandara, David R.
Τόπος έκδοσης J Thorac Oncol (2019)

JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer

ανά Shien, Kazuhiko, Papadimitrakopoulou, Vassiliki A., Ruder, Dennis, Behrens, Carmen, Shen, Li, Kalhor, Neda, Song, Juhee, Lee, J. Jack, Wang, Jing, Tang, Ximing, Herbst, Roy S., Toyooka, Shinichi, Girard, Luc, Minna, John D., Kurie, Jonathan M., Wistuba, Ignacio I., Izzo, Julie G.
Τόπος έκδοσης Mol Cancer Ther (2017)

Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC

ανά Lam, Vincent K., Zhang, Jianjun, Wu, Carol C., Tran, Hai T., Li, Lerong, Diao, Lixia, Wang, Jing, Rinsurongkawong, Waree, Raymond, Victoria M., Lanman, Richard B., Lewis, Jeff, Roarty, Emily B., Roth, Jack, Swisher, Stephen, Lee, J. Jack, Gibbons, Don L., Papadimitrakopoulou, Vassiliki A., Heymach, John V.
Τόπος έκδοσης J Thorac Oncol (2020)

A PHASE II STUDY OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH c-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY S1400K, NCT03574753)

ανά Waqar, Saiama N, Redman, Mary W, Arnold, Susanne M, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Gandara, David R, Stinchcombe, Thomas E, Leighl, Natasha B, Ramalingam, Suresh S, Tanna, Saloni H, Raddin, Ryan S, Minichiello, Katherine, Bradley, Jeffrey D, Kelly, Karen, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A
Τόπος έκδοσης Clin Lung Cancer (2020)

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

ανά Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Τόπος έκδοσης JAMA Oncol (2021)

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

ανά Langer, Corey J, Gadgeel, Shirish M, Borghaei, Hossein, Papadimitrakopoulou, Vassiliki A, Patnaik, Amita, Powell, Steven F, Gentzler, Ryan D, Martins, Renato G, Stevenson, James P, Jalal, Shadia I, Panwalkar, Amit, Yang, James Chih-Hsin, Gubens, Matthew, Sequist, Lecia V, Awad, Mark M, Fiore, Joseph, Ge, Yang, Raftopoulos, Harry, Gandhi, Leena
Τόπος έκδοσης Lancet Oncol (2016)

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

ανά Gong, Ke, Guo, Gao, Gerber, David E., Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D., Hatanpaa, Kimmo J., Kernstine, Kemp, Cai, Ling, Xie, Yang, Zhu, Hong, Fattah, Farjana J., Zhang, Shanrong, Takahashi, Masaya, Mukherjee, Bipasha, Burma, Sandeep, Dowell, Jonathan, Dao, Kathryn, Papadimitrakopoulou, Vassiliki A., Olivas, Victor, Bivona, Trever G., Zhao, Dawen, Habib, Amyn A.
Τόπος έκδοσης J Clin Invest (2018)